146 related articles for article (PubMed ID: 15816556)
1. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.
Pal A; Khan S; Wang YF; Kamath N; Sarkar AK; Ahmad A; Sheikh S; Ali S; Carbonaro D; Zhang A; Ahmad I
Anticancer Res; 2005; 25(1A):331-41. PubMed ID: 15816556
[TBL] [Abstract][Full Text] [Related]
2. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
Lei S; Chien PY; Sheikh S; Zhang A; Ali S; Ahmad I
Anticancer Drugs; 2004 Sep; 15(8):773-8. PubMed ID: 15494639
[TBL] [Abstract][Full Text] [Related]
3. Preparation, Pharmacokinetic Profile, and Tissue Distribution Studies of a Liposome-Based Formulation of SN-38 Using an UPLC-MS/MS Method.
Li K; Wang S
AAPS PharmSciTech; 2016 Dec; 17(6):1450-1456. PubMed ID: 26831446
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.
Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z
Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262
[TBL] [Abstract][Full Text] [Related]
5. SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study.
Fang YP; Chuang CH; Wu YJ; Lin HC; Lu YC
Int J Nanomedicine; 2018; 13():2789-2802. PubMed ID: 29785106
[TBL] [Abstract][Full Text] [Related]
6. Determination by liquid chromatography with fluorescence detection of total 7-ethyl-10-hydroxy-camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38).
Guo W; Ahmad A; Khan S; Dahhani F; Wang YF; Ahmad I
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 791(1-2):85-92. PubMed ID: 12798168
[TBL] [Abstract][Full Text] [Related]
7. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
[TBL] [Abstract][Full Text] [Related]
8. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
9. A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38).
Khan S; Ahmad A; Guo W; Wang YF; Abu-Qare A; Ahmad I
J Pharm Biomed Anal; 2005 Feb; 37(1):135-42. PubMed ID: 15664753
[TBL] [Abstract][Full Text] [Related]
10. Single protein encapsulated SN38 for tumor-targeting treatment.
Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
[TBL] [Abstract][Full Text] [Related]
11. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
[TBL] [Abstract][Full Text] [Related]
12. [Irinotecan pharmacokinetics].
Chabot GG; Robert J; Lokiec F; Canal P
Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
[TBL] [Abstract][Full Text] [Related]
13. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
14. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors.
Marier JF; Pheng L; Trinh MM; Burris HA; Jones S; Anderson K; Warner S; Porubek D
J Pharm Sci; 2011 Oct; 100(10):4536-45. PubMed ID: 21630281
[TBL] [Abstract][Full Text] [Related]
17. A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7-ethyl-10-hydroxycamptothecin (SN-38) in human plasma containing liposome-based SN-38 (LE-SN38).
Khan S; Ahmad A; Ahmad I
Biomed Chromatogr; 2003 Dec; 17(8):493-9. PubMed ID: 14648604
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of a novel liposome-based formulation of SN-38.
Zhang JA; Xuan T; Parmar M; Ma L; Ugwu S; Ali S; Ahmad I
Int J Pharm; 2004 Feb; 270(1-2):93-107. PubMed ID: 14726126
[TBL] [Abstract][Full Text] [Related]
19. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
Adkins CE; Nounou MI; Hye T; Mohammad AS; Terrell-Hall T; Mohan NK; Eldon MA; Hoch U; Lockman PR
BMC Cancer; 2015 Oct; 15():685. PubMed ID: 26463521
[TBL] [Abstract][Full Text] [Related]
20. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
Ramsay EC; Anantha M; Zastre J; Meijs M; Zonderhuis J; Strutt D; Webb MS; Waterhouse D; Bally MB
Clin Cancer Res; 2008 Feb; 14(4):1208-17. PubMed ID: 18281556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]